The estimated Net Worth of Waleed H Hassanein is at least $42 Million dollars as of 21 August 2024. Waleed Hassanein owns over 45,000 units of TransMedics stock worth over $12,460,130 and over the last 5 years he sold TMDX stock worth over $26,425,438. In addition, he makes $3,159,300 as President, Chief Executive Officer, and Director at TransMedics.
Waleed has made over 40 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of TMDX stock worth $723,600 on 21 August 2024.
The largest trade he's ever made was exercising 193,074 units of TransMedics stock on 10 March 2023 worth over $426,694. On average, Waleed trades about 26,364 units every 41 days since 2019. As of 21 August 2024 he still owns at least 86,643 units of TransMedics stock.
You can see the complete history of Waleed Hassanein stock trades at the bottom of the page.
Dr. Waleed H. Hassanein M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989, and holds a General Certificate of Education from the University of London. Hassanein is qualified to serve on our board of directors because of his extensive experience in the medical field and his extensive knowledge of our company based on his role as founder and President and Chief Executive Officer.
As the President, Chief Executive Officer, and Director of TransMedics, the total compensation of Waleed Hassanein at TransMedics is $3,159,300. There are no executives at TransMedics getting paid more.
Waleed Hassanein is 51, he's been the President, Chief Executive Officer, and Director of TransMedics since . There are 14 older and 1 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
Waleed's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein, and James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: